Research using BioIVT's TRANSPORTER CERTIFIED™ hepatocytes in sandwich culture and HEPATOPAC® technology in vitro liver models will be presented.
WESTBURY, NY - Jun 28, 2018 - BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
ISSX is one of the largest scientific societies dedicated to investigating the metabolism and disposition of chemicals in biological systems. As a result, its activities are relevant to all aspects of drug development and toxicology.
Biopharmaceutical companies want to conduct toxicology studies as early as possible in their drug development programs so that they can identify candidates that are going to have safety issues during the preclinical phase, said Kenneth Brouwer, PhD, RPh, vice president, ADME-Tox at BioIVT. We welcome this opportunity to support ISSX and highlight some of the promising toxicology research being conducted using our HEPATOPAC technology, TRANSPORTER CERTIFIED hepatocytes, and ADMET PHASEZERO® Research Services.
BioIVTs HEPATOPAC technology is used to create stable in vitro liver models that permit long-term hepatic metabolism and toxicity studies.
The companys TRANSPORTER CERTIFIED hepatocytes, when cultured in sandwich culture, closely reflect physiologic conditions because the hepatocytes express functioning uptake and efflux transporters and develop bile pockets similar to bile canaliculi.
BioIVTs PHASEZERO Research Services team works collaboratively with clients, providing expertise and guidance to help advance their drug development programs. BioIVTs ADME Tox scientists design and implement programs to address clients liver-related research questions. With a broad portfolio of hepatic products and technologies, and extensive experience, BioIVT recommends comprehensive research programs customized to meet clients objectives and the characteristics of their compounds.
BioIVT is participating in the following ISSX sessions:
Monday, July 16
Poster
1:30-2:00 pm
Jonathan Jackson, PhD, BioIVT study director, will present poster #P50 entitled An Integrated In Vitro Screen Using Sandwich-cultured Human Hepatocytes for Prediction of Cholestatic Hepatotoxicity.
Tuesday, July 17
Industry-sponsored Symposium
7:30-8:30 am
BioIVT is sponsoring the symposium entitled Applications of a Micropatterned Co-cultured Hepatocyte System to Support Small Molecule Drug Discovery presented by T. Eric Ballard, PhD, principal scientist in the Biotransformation Group in Pharmacokinetics, Dynamics, and Metabolism at Pfizer.
Presentation
2:30-5:00 pm
Scott Heyward, PhD, BioIVT director, research and development and scientific affairs, will give the opening remarks at the 14th Annual Assembly of the Hepatocyte Research Association. This years meeting, which addresses P450 Enzyme Induction: A Deeper Dive, will explore how human and animal hepatocytes communicate with each other. It will also provide attendees with practical information about using hepatocytes in their research.
In addition, BioIVT PHASEZERO Research Services consultants will be available to answer technical questions about the companys toxicology research products and services in booth #407.
For further information about the North American ISSX Meeting, please visit
http://www.issx2018.com
.
About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit
www.bioivt.com
or follow the company on Twitter @BioIVT.